CR10699A - Antagonistas de wnt y su uso en el diagnostico y tratamiento de trastornos mediados por wnt - Google Patents

Antagonistas de wnt y su uso en el diagnostico y tratamiento de trastornos mediados por wnt

Info

Publication number
CR10699A
CR10699A CR10699A CR10699A CR10699A CR 10699 A CR10699 A CR 10699A CR 10699 A CR10699 A CR 10699A CR 10699 A CR10699 A CR 10699A CR 10699 A CR10699 A CR 10699A
Authority
CR
Costa Rica
Prior art keywords
wnt
diagnosis
treatment
antagonists
disorders
Prior art date
Application number
CR10699A
Other languages
English (en)
Inventor
James A Ernst
Paul Plakis
Bonnee Rubinfeld
Venita Dealmeida
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CR10699A publication Critical patent/CR10699A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
CR10699A 2006-09-08 2009-03-31 Antagonistas de wnt y su uso en el diagnostico y tratamiento de trastornos mediados por wnt CR10699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82506306P 2006-09-08 2006-09-08
US95117507P 2007-07-20 2007-07-20

Publications (1)

Publication Number Publication Date
CR10699A true CR10699A (es) 2009-07-10

Family

ID=39092004

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10699A CR10699A (es) 2006-09-08 2009-03-31 Antagonistas de wnt y su uso en el diagnostico y tratamiento de trastornos mediados por wnt

Country Status (19)

Country Link
US (5) US7947277B2 (es)
EP (1) EP2061495A2 (es)
JP (1) JP2010504081A (es)
KR (1) KR20090060334A (es)
AR (1) AR062709A1 (es)
AU (1) AU2007292242A1 (es)
BR (1) BRPI0714751A2 (es)
CA (1) CA2662041A1 (es)
CL (1) CL2007002609A1 (es)
CR (1) CR10699A (es)
IL (1) IL197240A0 (es)
MA (1) MA31135B1 (es)
MX (1) MX2009002522A (es)
NO (1) NO20091413L (es)
PE (3) PE20120806A1 (es)
RU (1) RU2009113023A (es)
SG (2) SG174101A1 (es)
TW (1) TW200819463A (es)
WO (1) WO2008031009A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2628116A1 (en) 2005-10-31 2007-12-13 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP2009065938A (ja) * 2007-09-14 2009-04-02 Matsumoto Shika Univ タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法
WO2009074637A1 (en) * 2007-12-13 2009-06-18 Merck Serono S.A. Sarp-1 fusion proteins and uses thereof
EP2274622B1 (en) 2008-04-30 2014-10-08 The Governing Council of the University of Toronto Use of sfrp-3 in the assessment of heart failure
ES2334092B1 (es) * 2008-07-02 2011-01-24 Proyecto De Biomedicina Cima, S.L. Agentes antiangiogenicos.
WO2010037041A2 (en) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
JP5727226B2 (ja) 2008-09-30 2015-06-03 協和発酵キリン株式会社 Ｆｒｉｚｚｌｅｄ１、Ｆｒｉｚｚｌｅｄ２又はＦｒｉｚｚｌｅｄ７細胞外システインリッチドメインを含む蛋白質を含有する骨疾患治療用医薬組成物
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
US20110189097A1 (en) * 2009-11-09 2011-08-04 Dritan Agalliu Use of WNT inhibitor to inhibit angiogenesis in the CNS
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en) * 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2012006027A1 (en) * 2010-06-28 2012-01-12 Five Prime Therapeutics, Inc. Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules and treatments using same
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
EP2630154A1 (en) 2010-10-20 2013-08-28 F.Hoffmann-La Roche Ag Methods and compositions for modulating the wnt pathway
KR102077871B1 (ko) * 2010-11-16 2020-02-14 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
CA2818992C (en) 2010-12-01 2021-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
EP3281640A1 (en) 2011-06-17 2018-02-14 President and Fellows of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
JP6121902B2 (ja) 2011-06-21 2017-04-26 協和発酵キリン株式会社 Ｆｒｉｚｚｌｅｄ２の細胞外領域蛋白質のトランケート体を含む蛋白質、および該蛋白質を含有する骨疾患治療用医薬組成物
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
US20130216546A1 (en) * 2012-01-10 2013-08-22 Ngm Biopharmaceuticals, Inc. Methods of Treating Glucose Metabolism Disorders
JP6545959B2 (ja) 2012-02-11 2019-07-17 ジェネンテック， インコーポレイテッド Ｒスポンジン転位およびその使用方法
WO2013126006A1 (en) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
WO2014066328A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
EP2935335B1 (en) * 2012-12-19 2020-10-28 Affibody AB New polypeptides
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP3077546A4 (en) 2013-12-02 2017-04-26 Oncomed Pharmaceuticals, Inc. Identification of predictive biomarkers associated with wnt pathway inhibitors
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
KR101572606B1 (ko) * 2014-11-24 2015-11-27 강원대학교산학협력단 Sfrp5 유래의 펩타이드 및 이를 포함하는 피부 미백용 화장료 조성물
WO2016126054A1 (ko) 2015-02-04 2016-08-11 (주)메드팩토 변형된 ｄｋｋ2 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 이를 이용한 방법
WO2017165398A1 (en) * 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
CN108310366A (zh) * 2017-01-15 2018-07-24 复旦大学附属华山医院 重组sfrp5蛋白在制备治疗非酒精性脂肪性肝炎药物中的用途
EP4061848A4 (en) * 2019-11-18 2024-03-20 The Regents of the University of California ANTI-ROR-2 ANTIBODIES AND METHODS OF USE
JP2023503615A (ja) * 2019-11-26 2023-01-31 シーダーズ－サイナイ メディカル センター 循環からミトコンドリアｄｎａ又はゲノムｄｎａを枯渇させることにより疾患及び症状を治療する組成物及び方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039357A1 (en) 1996-04-12 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University Wnt RECEPTOR COMPOSITIONS AND METHODS
DK0932678T4 (da) 1996-09-24 2010-07-12 Genentech Inc En familie af gener kodende for apoptoserelaterede peptider, peptider kodet deraf og fremgangsmåder til anvendelse deraf
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
CA2414015A1 (en) 2000-06-21 2001-12-27 Incyte Genomics, Inc. Human receptors
US7413873B2 (en) 2001-01-30 2008-08-19 The Regents Of The University Of California Method of detection and treatment of colon cancer
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
AU2002308557A1 (en) 2001-05-01 2002-11-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
WO2003004045A2 (en) 2001-07-05 2003-01-16 Xenon Genetics, Inc. Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
US20030108963A1 (en) 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
WO2004032838A2 (en) * 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
US7803783B2 (en) 2002-12-06 2010-09-28 The Board Of Trustees Of The Leland Stanford Junior University Use of WNT inhibitors to augment therapeutic index of chemotherapy
AU2003293408A1 (en) * 2002-12-06 2004-06-30 The Board Of Trustees Of The Leland Stanford Junior University PROTECTION OF STEM CELLS FROM CYTOTOXIC AGENTS BY MODULATION OF Beta-CATENIN SIGNALING PATHWAYS
US20050096263A1 (en) 2003-10-30 2005-05-05 Keay Susan K. Novel antiproliferative factor and methods of use
CA2580780A1 (en) 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Frizzled proteins and detection and treatment of cancer
WO2006034328A2 (en) 2004-09-21 2006-03-30 Rhode Island Hospital, A Lifespan-Partner Wnt proteins and detection and treatment of cancer
WO2006036175A2 (en) 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Wnt proteins and detection and treatment of cancer
US8809287B2 (en) 2004-11-15 2014-08-19 Icahn School Of Medicine At Mount Sinai Compositions and methods for altering Wnt autocrine signaling
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth

Also Published As

Publication number Publication date
SG174101A1 (en) 2011-09-29
BRPI0714751A2 (pt) 2014-06-24
CL2007002609A1 (es) 2008-04-18
JP2010504081A (ja) 2010-02-12
EP2061495A2 (en) 2009-05-27
PE20120806A1 (es) 2012-07-25
PE20081217A1 (es) 2008-09-24
MX2009002522A (es) 2009-06-19
KR20090060334A (ko) 2009-06-11
SG174100A1 (en) 2011-09-29
US7947277B2 (en) 2011-05-24
IL197240A0 (en) 2011-08-01
PE20120807A1 (es) 2012-07-26
AR062709A1 (es) 2008-11-26
WO2008031009A2 (en) 2008-03-13
RU2009113023A (ru) 2010-10-20
US20170349639A1 (en) 2017-12-07
TW200819463A (en) 2008-05-01
MA31135B1 (fr) 2010-02-01
US20080299136A1 (en) 2008-12-04
US20100266593A1 (en) 2010-10-21
CA2662041A1 (en) 2008-03-13
US20120141481A1 (en) 2012-06-07
AU2007292242A1 (en) 2008-03-13
WO2008031009A3 (en) 2009-07-02
US20110311534A1 (en) 2011-12-22
NO20091413L (no) 2009-06-08

Similar Documents

Publication Publication Date Title
CR10699A (es) Antagonistas de wnt y su uso en el diagnostico y tratamiento de trastornos mediados por wnt
NL301192I2 (nl) Finerenon en zijn zouten, solvaten en solvaten van de zouten daarvan
CR10847A (es) Compuesto heteromonociclico y uso del mismo
HK1142777A1 (en) Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma lingo-1 trkb
HK1146596A1 (en) Use of lingo-4 antagonists in the treatment of conditions involving demyelination lingo-4
CL2007002327A1 (es) Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
BRPI1005292A2 (pt) composição de decapagem e uso da composição
BRPI0815204A2 (pt) Dispositivo de administração fecal e utilização do dispositivo
BRPI0817298A2 (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI0913822A2 (pt) forma farmacêutica oral e uso da forma farmacêutica
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
BRPI0816835A2 (pt) dispositivo de pulverização e método de uso do mesmo
BRPI0919903A2 (pt) dispositivo de mobilização corporal e utilização do dispositivo
BRPI0719345A2 (pt) Di-hidroimidazóis substituídos e seu uso no tratamento de tumores.
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
BRPI0810475A2 (pt) uso de dimiracetam no tratamento de dor crônica
DK2124997T3 (da) Anvendelse af IL-1-antagonister til behandling af gigt og pseudogigt
CR10430A (es) Aminothiazoles and their uses
BRPI0818121A2 (pt) diespiro 1,2,4-trioxolano e seus métodos de fabricação e utilização
DK3156057T3 (da) Delmopinol-belagt dyretyggeartikel til anvendelse til forebyggelsen eller behandlingen af halitosis